NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

January 12, 2023

Jorge M. Mercado, MD, discusses the evolution of biopsy techniques in patients with lung cancer.

January 11, 2023

Vamsidhar Velcheti, MD, highlights the advancement of CTLA-4–based combinations in non–small cell lung cancer treatment, the emergence of antibody-drug conjugates in non–small cell lung cancer, and the impact of the POSEIDON trial on the treatment landscape.

January 04, 2023

Vamsidhar Velcheti, MD, discusses the evaluation of immunotherapy combination regimens for patients with metastatic non–small cell lung cancer.

December 14, 2022

Jorge M. Mercado, MD, discusses the effect of the COVID-19 pandemic on lung cancer screening.

December 11, 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

October 06, 2022

Dr Velcheti discusses planned research into whether mobile technology services can improve patient outcomes for underserved and underrepresented patient populations.

September 28, 2022

NYU Langone Health has been recognized as No. 1 in quality and safety for inpatient and ambulatory care by Vizient, Inc.

September 18, 2022

To really advance equity in cancer care, we must think long and hard about where we apply innovation and how we measure success.

September 15, 2022

During the past 15 years, breakthrough discoveries have revolutionized the treatment landscape for most patients with lung cancer, progress that has helped fuel an overall drop in cancer mortality.

August 31, 2022

Aasma Shaukat, MD, MPH, discusses the benefit of diverse enrollment in clinical trials in colorectal cancer.

July 25, 2022

David R. Wise, MD, PhD, discusses unmet needs in the standard of care in prostate cancer.

June 07, 2022

Vamsidhar Velcheti, MD, discusses the safety of nemvaleukin alfa in patients with advanced solid tumors in the phase 1/2 ARTISTRY-1 trial.

June 07, 2022

Adagrasib led to an intracranial objective response rate of 32% and a median intracranial duration of response that was not reached in patients with KRAS G12C–mutant non–small cell lung cancer and active, untreated CNS metastases, according to findings from the KRYSTAL-1 trial.

May 17, 2022

Paul E. Oberstein, MD, discusses remaining challenges in metastatic colorectal cancer.

May 17, 2022

Paul E. Oberstein, MD, discusses the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer.

April 18, 2022

Paul E. Oberstein, MD, discusses the utilization of ctDNA in metastatic colorectal cancer.

April 14, 2022

Dr D’Abreo discusses adverse effects that are common in metastatic breast cancer, shares advice on establishing an open channel of communication with patients, and highlights preventive and proactive management strategies for treatment-related adverse effects.

April 13, 2022

Paul E. Oberstein, MD, discusses the current treatment landscape of colorectal cancer.

March 21, 2022

Oliva Lara, MD, discusses the connection between molecular differences and disparities in cancer care in uterine serous carcinomas, as examined in a retrospective cohort study.

February 04, 2022

Faith E. Davies, MD, a nationally renowned hematology expert, has been appointed the inaugural director of the Center for Blood Cancers at NYU Langone Health’s Perlmutter Cancer Center.